Compare Carlyle Group Inc (CG) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs ClearPoint Neuro Inc — how do they compare? Carlyle Group Inc trades at $47.8 (market cap $17.23B), while ClearPoint Neuro Inc trades at $14.98 (market cap $454.21M). The key difference: Carlyle Group Inc is far larger — about 37.9× ClearPoint Neuro Inc's market cap, and Carlyle Group Inc pays a 2.9% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CG | CLPT | |
|---|---|---|
Market Cap | $17.23B | $454.21M |
Sector | Financials | Health |
52-Week High | $69.35 | $29.60 |
52-Week Low | $40.52 | $8.66 |
Dividend Yield | 2.9% | — |
Enterprise Value | — | $488.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CG trades at $47.80, up 0.02% daily, with a bullish technical signal from moving averages and a consensus analyst price target of $59.14. Recent Q2 2026 earnings beat expectations, with EPS of $1.07 versus $0.91 expected, while revenue trends show volatility, declining to $2.8B in 2026 from $3.2B in 2025. The company maintains a dividend of $0.35 per share and has strong institutional interest, with 53.84% of analysts rating it a Buy.
The outlook for CG is positive due to earnings beats and analyst optimism, but risks include inconsistent cash flow from operations and declining revenue. Investment opportunity lies in potential upside to the price target, supported by fundraising strength and strategic partnerships, though investors should monitor execution risks and macroeconomic pressures.
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
